Elekta to buy Nucletron for $524M

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Elekta has signed a definitive agreement to acquire Nucletron for EUR365 million ($524.39 million U.S.) in cash. After the aquisition is completed, Elekta said it will offer radiotherapy planning and delivery technologies with the addition of Nucletron's brachytherapy treatment planning and delivery systems.

The Veenendaal, Netherlands-based Nucletron will add 1,000 new customers to Elekta’s customer base of more than 5,000, according to the companies.

Under the terms of the agreement, Elekta will acquire Nucletron on a cash and debt-free basis. The transaction, which has been approved by the board of directors of both companies, is subject to regulatory approval and is expected to close in early autumn 2011.

The acquisition is expected to be accretive to Elekta’s cash earnings within 12 months, according to the Stockholm, Sweden-based company. The transaction will be financed through existing cash on hand and available credit facilities. The pro forma business will continue to have a strong financial profile. The transaction remains subject to regulatory approval and is expected to close in early autumn.
 
BoA Merrill Lynch served as Elekta’s exclusive financial advisor on the transaction, and NautaDutilh served as its legal counsel. Jefferies International served as exclusive financial adviser to Nucletron. Allen & Overy served as Nucletron’s legal counsel.

Justine Varieur Cadet

Related Content

Imaging may be misleading when determining the success of cancer treatment
Prostate cancer radiotherapy timeline can be safely shortened
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
VI-RADS threshold, imaging features predict bladder cancer invasiveness with nearly 100% accuracy
PHOTO GALLERY: thyroid nodule imaging

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.